clinical trial · NCT07918898
Comparison of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart
Healthy ParticipantsGZR101 80 InjectionGZR33 InjectionInsulin Aspart Injection
brief summary
This trial is conducted in China. This study will be conducted to evaluate pharmacokinetic/pharmacodynamic characteristics and safety of single administration of GZR101-80 Injection with separately injected, simultaneous doses of GZR33 Injection and Insulin Aspart in healthy participants
started
Oct 29, 2026
primary completion
Feb 2, 2027
completion
Feb 2, 2027
last updated
Nov 5, 2026
official title
A Phase I Study Comparing Pharmacokinetic/Pharmacodynamic Characteristics and Safety of Single Administration of GZR101-80 Injection With Separately Injected, Simultaneous Doses of GZR33 Injection and Insulin Aspart in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol